Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
13.56
+0.05 (0.37%)
At close: Aug 13, 2025, 4:00 PM
14.00
+0.44 (3.24%)
Pre-market: Aug 14, 2025, 8:47 AM EDT
Mineralys Therapeutics Employees
Mineralys Therapeutics had 51 employees as of December 31, 2024. The number of employees increased by 23 or 82.14% compared to the previous year.
Employees
51
Change (1Y)
23
Growth (1Y)
82.14%
Revenue / Employee
n/a
Profits / Employee
-$3,740,647
Market Cap
883.78M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51 | 23 | 82.14% |
Dec 31, 2023 | 28 | 16 | 133.33% |
Dec 31, 2022 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MLYS News
- 1 day ago - Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 - GlobeNewsWire
- 6 weeks ago - Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat - GlobeNewsWire
- 2 months ago - Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga
- 2 months ago - Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria - GlobeNewsWire
- 2 months ago - Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - GlobeNewsWire
- 3 months ago - Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - GlobeNewsWire